<DOC>
	<DOCNO>NCT01692704</DOCNO>
	<brief_summary>An open label , prospective , non-randomized single arm study . Combination two treatment modality - HAI FUDR systemic chemotherapy cisplatin gemcitabine . Definition maximum tolerate dose ( MTD ) intravenous gemcitabine combination intravenous cisplatin intra-arterial FUDR . Definition safety toxicity combine regional systemic treatment approach . Definition response rate 3 month hepatic intra-arterial chemotherapy continuous infusion FUDR without ligation right leave portal vein , combination 3 month systemic cisplatin gemcitabine patient unresectable intrahepatic hilar CCC . A total 9-18 patient require . 3-6 patient per dose level . A maximum three dose level ( 1 - 3 ) define . Statistical Methodology : Traditional 3+3 dose algorithm find MTD . - Trial medicinal product</brief_summary>
	<brief_title>Downsizing Unresectable Cholangiocarcinoma Combined Intravenous Intra-arterial Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically proven cholangiocellular carcinoma include gallbladder cancer . Nonresectable cholangiocellular carcinoma judge within interdisciplinary tumorboard include senior hepatobiliary surgeon . Non resectability base insufficient remnant liver volume . Patient candidate liver transplantation WHO Performance Score 0 1 No extrahepatic tumor , evaluate PET/CT scan chest abdomen/pelvis exception potentially resectable small lung nodule hilar lymph node involvement . The assessment do within 21 day registration . Adequate liver function kidney function test , include follow : Bilirubin &lt; 2 x ULN AspartateAminotransferase ( AST ) &lt; 5 x ULN AlanineAminotransferase ( ALT ) &lt; 5 x ULN Alkaline phosphatase &lt; 5 x ULN Estimated creatinine clearance &gt; 60 ml/min ( use Cockcroft formula ) Adequate hematological value : Hemoglobin &gt; 80 G/L Leucocytes &gt; 3.00 G/L , Neutrophils &gt; 1.00 G/Ll Platelets &gt; 100 G/L Signed write informed consent Patient age &gt; /= 18 year Presentation case interdisciplinary tumorboard attend hepatobiliary surgeon , oncologist , hepatologists radiologist Women breastfeed use effective contraception sexually active , pregnant agree become pregnant 12 month thereafter . A negative pregnancy test inclusion trial require woman &lt; 50 year . Men agree father child participation trial 12 month thereafter . Patient compliance geographic proximity allow proper stag follow . Exclusion criterion : Anatomic variant arteriogram prevents selective delivery chemotherapy liver Life expectancy &lt; 3 month Severe medical psychiatric comorbidity prohibit plan treatment give informed consent Any man woman childbearing age case inadequate contraception Pregnancy breastfeed woman Known hypersensitivity trial drug hypersensitivity component trial drug . Treatment clinical trial within 30 day prior trial entry . Active heart disease define congestive heart failure &gt; NYHA class 2 Past current history ( within last 2 year prior treatment start ) malignancies except basal squamous cell carcinoma skin situ carcinoma cervix Inability unwillingness comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>